tetanus toxoid ccl3 improve dendritic cell vaccines mice glioblastoma patients
stimulation dendritic cellsdcs mature andmigrate draining lymph nodes induce immune responses autologous dcs generated ex vivo pulsed tumour antigens injected back patients immunotherapy dc vaccines shown limited promise treatment patients advanced cancers- including glioblastoma- factors dictating dc vaccine efficacy remain poorly understood show pre-conditioning vaccine site potent recall antigen tetanus/diphtheria td toxoid can significantly improve lymph node homing efficacy tumour-antigen-specific dcs assess effect vaccine site pre-conditioning humans randomized patients glioblastoma pre-conditioning either mature dcs8 td unilaterally bilateral vaccination dcs pulsed cytomegalovirus phosphoprotein pp65 rna laboratories shown pp65 expressed % glioblastoma specimens surrounding normal brain- providing unparalleled opportunity subvert viral protein tumour-specific target patients given td enhanced dc migration bilaterally significantly improved survival mice td pre-conditioning also enhanced bilateral dc migration suppressed tumour growth manner dependent chemokine ccl3 clinical studies corroborating investigations mice suggest pre-conditioning potent recall antigen may represent viable strategy improve anti-tumour immunotherapy
